Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Asmaa M ZahranAmal RayanZeinab Albadry M ZahranWael M Y MohamedDalia O MohamedMona H Abdel-RahimOmnia El-BadawyPublished in: PloS one (2022)
The CD39 and PD1 inhibitory pathways are synergistically utilized by TNBC cells to evade host immune response causing poor survival. Hence, combinational immunotherapy blocking these pathways might be a promising treatment strategy in this type of cancer.